Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1621 | 7,3',4'-Trihydroxy-3-benzyl-2H-chromene |
| 1. 7,3',4'-Trihydroxy-3-benzyl-2H-chromene is a Potential xanthine oxidase inhibitor. | |
| BCN1636 | Quinovic acid 3-O-alpha-L-rhamnopyranoside |
| 1. Quinovic acid 3-O-alpha-L-rhamnopyranoside shows significant inhibitory activity against snake venom phosphodiesterase-I. | |
| BCN1653 | Rocaglaol |
| 1. Rocaglaol is a cytotoxic cyclopenta[b]benzofuran, shows in vitro cytotoxic activity against Lu1, LNCaP and MCF-7 cells with ED50 values of 13.8, 23.0 and 9.2 nM, respectively. 2. Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. 3. Rocaglaol can reduce tissue inflammation and neuronal cell death by inhibiting NF-kappa B and AP-1 signaling, resulting in significant neuroprotection in animal models of neurodegeneration. 4. Rocaglaol derivatives can prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. 5. Rocaglaol, pyrimidinone and aglaiastatin are potent inhibitors of the growth of K--cells, with IC50 values of 1-10 ng/mL, and induce normal morphology in K--cells at 10-30 ng/mL, they also specifically inhibit protein synthesis. | |
| BCN1659 | 3-O-Methylquercetin tetraacetate |
| 1. Quercetin 3-O-methyl ether is a potent phosphodiesterase (PDE)3/4 inhibitor, it has potential for treating asthma against ovalbumin-induced airway hyperresponsiveness . | |
| BCN1668 | Gallic acid |
| Gallic acid, is a histone acetyltransferase inhibitor and a potent inhibitor of brush border sucrase and other disaccharidases, which has powerful antioxidant, anti-tumor, and anti-tyrosinase activities. It can potentially interfere with the digestive functions of the intestine. It can efficiently block neuronal cell death by downregulating the expression of cytokines and the in vivo levels of NF-κB acetylation, is a possible therapeutic approach for alleviating the inflammatory progression of Alzheimer disease. | |
